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The Role of Microbiologic Agents in the Progression
of the Atherosclerosis: a Comprehensive Review
Ahmet Karabulut a,b,*
a
b

Department of Cardiology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey
Department of Medical Biotechnology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey

Abstract
Atherosclerosis is a leading cause of disability, morbidity and mortality in the world. Atherosclerosis is accepted as a
chronic progressive inﬂammatory disease. The inﬂammatory cascade in the vascular wall is well-deﬁned. However, the
predictors and contributors of the inﬂammatory response in atherosclerosis are not completely understood. Systemic and
local inﬂammation, which enhance the burden of inﬂammation in the vascular wall, have been proposed as risk factors
for the progression of atherosclerosis. Infectious micro-organisms are one of the major triggering factors for local and
systemic inﬂammation. In this review, we aimed to emphasize the linkage between micro-organisms and the progression
of atherosclerosis. We brieﬂy summarize the current medical literature and discuss the future perspectives of the linkage
between microbial agents and atherosclerosis representing cause and effect.
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1. Introduction

A

therosclerosis is accepted as a chronic and
progressive inﬂammatory disease [1]. The
predictors and contributors of atherosclerosis are
multifactorial. Inﬂammation plays a central role
in the initiation and progression of atherosclerosis
[2]. In this review, we aimed to emphasize the role
of microbial agents in the progression and complications of the atherosclerotic process. Initially,
we summarize the early studies that showed the
direct isolation of microbial agents from atherosclerotic plaques. Then, we will focus on gastrointestinal ﬂora and discuss the impact of the oral
and gut microbiome in the progression of
atherosclerosis. We will also discuss the treatment
strategies for suppressing the inﬂammatory reaction in atherosclerosis. Finally, we will review
the future perspectives on this topic.

2. Deﬁnition of Atherosclerosis
Atherosclerosis is deﬁned as the accumulation of
fatty and ﬁbrous material in the intimal layer of the
artery [1]. Atherosclerosis is a leading cause of
morbidity and mortality all over the world. One
third of all deaths occur secondary to arteriosclerosis and complications of atherosclerosis [3].
Involvement of the coronary vessels leads to acute
coronary syndrome and myocardial infarction,
which is a major killer worldwide. Involvement of
the aorta and carotid vessels leads to a transient
ischemic attack or stroke, which are leading causes
of disability and mortality. Involvement of the peripheral vessels in the upper and lower extremities
leads to claudication, ulceration and amputation.
Moreover, the involvement of visceral vessels can
lead to other important clinical syndromes.
Atherosclerosis has traditionally been accepted as
the deposition of lipids within the vessel wall of
medium-sized and large arteries [3]. Several investigations have been performed that showed the
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clinical and demographic parameters that affect the
progression of atherosclerosis [3]. Nowadays, clinical and demographic predictors of atherosclerosis
have been deﬁnitively reported in numerous studies
[3]. Dyslipidemia, diabetes, hypertension, smoking,
sedentary lifestyle, genetic predisposition, dietary
factors and stress are major contributors to the
atherosclerotic process [3]. Low density lipoprotein
(LDL) cholesterol has been pointed out as a major
contributor to atherosclerosis. A decrease in LDL
cholesterol has been linked to fewer vascular events
and also to slowing down the atherosclerotic process
[3]. Nonetheless, effective cholesterol reduction is
not enough to stop or reverse the atherosclerotic
process. Further investigations have revealed that
the pathophysiology of atherosclerosis is more
complex, and the deposition of LDL cholesterol is
only a single factor in the progression of atherosclerosis [4]. Recently, atherosclerosis was deﬁned
as chronic inﬂammation of the vessel wall [3e5]. It
involves complex endothelial dysfunction induced
by elevated LDL-cholesterol, free radicals, infectious
microorganisms, shear stress, hypertension, toxins
and a combination of these factors, which lead to a
compensatory inﬂammatory response [3e5]. Moreover, rheumatic and autoimmune diseases that
trigger the inﬂammatory process in the body may
affect the development of atherosclerosis. Psoriasis,
rheumatoid arthritis and inﬂammatory bowel disease are examples of chronic systemic inﬂammatory
diseases that may accentuate the progression of
atherosclerosis.

3. Inﬂammatory Cascades in the Progression
of Atherosclerosis
The interection between lipids and immune activation is the hallmark of atherosclerosis. Both local
and systemic inﬂammatory response get involved in
the initiation and progression of atherosclerosis.
The initial step in atherosclerosis is endothelial
dysfunction characterized by decreased nitric oxide
synthesis [6]. Shear stress, especially in the curvature and branching points of the vessel, are the
major triggering factor for the initiation of atherosclerosis. Oxidative stress, free oxygen radicals, inﬂammatory mediators aggrevate the local effect of
shear stress which initiate local inﬂammation. The
next step is local oxidation of LDL-cholesterol and
its accumulation in the vessel wall. Immune activation against LDL cholesterol initiates the systemic
inﬂammatory response. The upregulation of cell
adhesion molecules facilitates the adherence and
transmigration of leukocytes into the vessel wall. T
cells recognize oxidized LDL, heat shock protein
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and shared microbial antigens via molecular mimicry and locally release proinﬂammatory cytokines.
The stimulation of macrophages by T-cell derived
cytokines leads to the uptake of oxidized LDL and
the formation of foam cells, a hallmark of the early
atherosclerotic reaction. These cells secrete matrix
metalloproteinases which lead to further progression of atherosclerosis [3,6].
The major drugs used in atherosclerosis, i.e. statins and renin-angiotensin inhibitors, partially
mediate their effects by modulating the immune
response and inﬂammation [3].

4. Inﬂammation As an Etiologic Factor in
Atherosclerosis
Inﬂammation in the atherosclerotic process was
previously thought to be a microbe-free, sterile reaction. However, recent investigations have suggested the impact of microbial agents in the
progression of atherosclerosis [2,5]. Several investigations have been performed to show the role
of microbial agents in atherosclerosis, although the
results were variable [7e10]. Early studies proposed
that Chlamydia pneumoniae, Helicobacter pylori and
Mycoplasma pneumoniae may have an impact on the
progression of atherosclerosis [8,9]. Recent investigations have mainly focused on the gastro-intestinal system ﬂora [11,12]. Moreover, certain types
of dental ﬂora have been isolated from atherosclerotic plaques [13]. The isolation of certain members
of the intestinal ﬂora has raised the questions about
the role of the microbiota in the progression of
atherosclerosis [12]. Indeed, microorganism colonization of atheroma may be a bystander phenomenon, rather than a causative linkage with the
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disease. All the investigation just showed the presence of the microorganism within the atheroma
plaques. Further in-vivo investigations may show
the direct effect of the microorganism within the
atheroma plaques more clearly. Nonetheless, the
direct isolation of microbial agents from the
atherosclerotic plaque is clinically very important
step to clarify atherosclerotic process. This linkage
may yield to the generation of different treatment
methods for the atherosclerosis. The inﬂammatory
reaction produced by microbial agents may trigger
the initial step of the atherosclerotic process and
may have a role in the acceleration and complications of the disease.

5. Pathophysiology of Microbial Agents and
Linkage to Atherosclerosis
Both oral and gut microbiota species are the wellknown etiologic agents of infective endocarditis.
Thus, antibiotic prophylaxis was recommended for
invasive procedures involving oral cavity and gastro-intestinal systems in the high-risk patients.
Recent studies showed that there would be a linkage
between atherosclerosis and microbial agents
including oral and gut ﬂora also. The exact mechanism of the hazardous effect of microbial agent in
the atherosclerosis still is not clear. Microbial agents
may inﬂuence the atherosclerotic process either in a
direct or indirect manner [14e17]. The isolation of
microbial DNA from atherosclerotic plaques supports the direct effect of microbes. Direct invasion of
the vascular wall may initiate the inﬂammatory reaction. The invasion of atherosclerotic plaques with
different microbial agents could lead to further
progression of the disease. Direct invasion of
vulnerable plaques after transient bacteremia may
lead to the rupture of plaques, which leads to
serious clinical events. Direct isolation of microbial
agents was carried out both on coronary and carotid
plaques [15,18]. Atherosclerotic progression in the
coronary arteries and carotid arteries are a major
site of complications and the occurrence of clinically
relevant disease. In light of the current medical
literature, we can conclude that the colonization of
the coronary and carotid vascular wall by certain
microbial agents may accelerate the disease and
may lead to clinically relevant complications earlier.
Indirect effects may become evident with the distant
production of inﬂammatory markers. Analysis of
atherosclerotic plaques has shown that there is
abundant production of cytokines and inﬂammatory
factors within plaques [15,16]. Microbial agents may
increase the systemic inﬂammatory reaction with
distant effects. Moreover, microbial agent also may

have indirect effects via some metabolites. Recent
studies have shown that accumulation of the proatherogenic factor trimethylamine-N-oxide (TMAO)
is linked to intestinal trimethylamine (TMA) production by certain strains of gut microbes [16,19].
The gut ﬂora also has an impact on cholesterol and
glucose balance. The indirect effects of the gut
microbiota seem to be more important than the
direct invasive effect.
5.1. Chlamydia pneumoniae
Chlamydia pneumoniae is a common cause of
respiratory tract infections. However, it has the
ability to disseminate systematically and may cause
chronic inﬂammation. It can easily disseminate
through peripheral blood mononuclear cells and
colonize extrapulmonary tissue, predominantly the
vascular wall [7]. C.pneumoniae was the ﬁrst microbial agent blamed for the progression of atherosclerosis. Long-term localization of C. pneumoniae in
the vessel wall may trigger an inﬂammatory
response, which may accelerate the atherosclerotic
process. Initial investigations showed that there was
a correlation between serologic positivity for C.
pneumoniae and atherosclerotic vascular diseases
[20]. Persistent infection with C. pneumoniae enhances the systemic inﬂammatory response, evidenced by high levels of C-reactive protein (CRP)
and IL-6. In vivo studies showed that atherosclerotic
lesions are exacerbated following C. pneumoniae
inoculation in hyperlipidemic animal models [16].
Further investigations with the direct isolation of C.
pneumoniae from the carotid and coronary atherosclerotic plaques ensured the direct effect of C.
pneumoniae in the atherosclerotic process. Persistent
infection with C. pneumoniae leads to the secretion of
proinﬂammatory cytokines such as TNF-a, IFN-g,
IL-1, IL-6, adhesion molecules and reactive oxygen
species. All of these pathways contribute to the local
and systemic chronic inﬂammatory reaction
responsible for the initiation, progression and
complication of atherosclerotic plaques [20]. C.
pneumoniae has been isolated from carotid plaques
in over half of reported cases [18,20e22]. In addition,
carotid plaques with C. pneumoniae infection are
more likely to be complicated by acute cerebrovascular accidents [19]. It has also been reported that
serum antibody levels for C. pneumoniae do not
predict the location of the bacteria within carotid
plaques. So, carotid plaque infection with C. pneumoniae may progress slowly and asymptomatically
as a local infection. A meta-analysis by Filardo et al.
concluded that C. pneumoniae infection may
contribute to atherosclerotic cardiovascular disease

by enhancing the inﬂammatory state; particularly,
seropositivity to C. pneumoniae IgA together with
high sensitive CRP, ﬁbrinogen and IL-6 may be
predictive of atherosclerotic cardiovascular risk [7].
Although most studies proposed the impact of
Chlamydia pneumonia in atherosclerosis, antibiotic
trials for the eradication of C. pneumonia failed to
reverse this connection. The limited ability of antibiotics to diffuse into atherosclerotic plaques might
be one reason for this. Additionally, after triggering
the local inﬂammatory reaction, C. pneumoniae may
return to a dormant form, on which antibiotic
therapy is useless. Finally, C. pneumoniae seems to
be only one infectious agent in the progression of
atherosclerosis. Recent studies concluded that there
are many microbial agents linked to atherosclerosis
[9]. So, even effective antibiotic treatment with the
eradication of C. pneumoniae would not be enough
the reverse the atherosclerotic process because of
the polymicrobial involvement of atherosclerotic
plaques.
After the correlation between C. pneumoniae and
atherosclerosis was described, other microorganisms were investigated that could lead to potential
chronic infections within the body. The most common pathogens proposed to have a relationship
with atherosclerosis are indicated in Table 1.
5.2. Other bacterial species
H. pylori, a bacterium associated with stomach
disease, has been reported as a predictor of
atherosclerosis [9]. Similar to C. pneumoniae, a
deﬁnitive effect of the eradication of H.pylori to
reverse atherosclerotic process is not clear.
M. pneumoniae is another respiratory pathogen
that tends to induce chronic disease with an atypical
presentation. Long-term infection with M.pneumoniae may enhance the inﬂammatory response in the
vascular wall [9].
5.3. Viruses
Some viral agents have also been reported as
predictors of atherosclerosis. Cytomegalovirus
(CMV), EpsteineBarr virus (EBV), hepatitis C virus
(HCV), hepatitis B virus (HBV), human immunodeﬁciency virus (HIV), enteroviruses and inﬂuenza
A have been reported as possible predictors of
atherosclerosis [23]. However, their impact on the
progression of atherosclerosis is variable. Cytomegalovirus is associated with an increased risk of
cardiac allograft vasculopathy and it is associated
with transplant rejection. It was shown that CMV
infection decreased the 10 year cardiac allograft

443

vasculopathy survival. The major mechanism of the
vasculopathy was proposed as immune-mediated
injury followed by inﬂammation [24]. Subsequent
smooth muscle cell migration from the vessel media
to the intima and proliferation lead to intimal hyperplasia and vessel narrowing. Cytomegalovirus
infection may play a role in the denovo atherosclerotic process by triggering similar pathway.
Besides bacteria and viruses, some protozoa and
fungi have also been isolated from atherosclerotic
plaques, which brings their impact up for discussion
[25].
5.4. Oral microbiota
Recent studies have primarily focused on oral and
gut microbiome and their effect on atherosclerosis
[16,26e28]. There are more than 700 species of
bacteria living in the oral ﬂora, and most of them
have not been cultivated. It is well-known that the
oral ﬂora may cause transient bacteremia after a
dental procedure, which may represent clinical evidence in patients with valvular heart disease.
Nonetheless, even simple tooth brushing may
trigger transient bacteremia. Each bacteremia attack
is a risk factor for a systemic inﬂammatory response.
On the other hand, most oral bacteria have poor
virulence and do not trigger a systemic inﬂammatory response. However, they are still capable of
producing a local inﬂammatory reaction. Transmission of such bacteria to the vascular wall and
atherosclerotic plaques may affect the atherosclerotic process. Recent medical data also support this
hypothesis [28e30]. The majority of carotid plaques
involve more than a single bacterium from the oral
microbiota, even when systemic inﬂammatory
markers are normal [31,32]. More frequent bacteremia periods may be associated with an accelerated
atherosclerotic process. Moreover, they may trigger
plaque rupture and serious clinical circumstances
during bacteremia. In each bacteremia episode,
different species may settle within the atherosclerotic plaque and trigger a further local inﬂammatory
reaction. So, the isolation of bacteria within plaques
does not give information about the timing of
bacteremia and infection. In such patients, hygiene
of the oral cavity is very important. However,
studies have shown that only certain species have a
connection with atherosclerosis.
Porphyromonas gingivalis was a well-known oral
microbe that has been proposed as a risk factor for
atherosclerosis [13]. Many studies have conﬁrmed
the role of the oral microbiota in the atherosclerotic
process [33e36]. Aggregatibacter, Proteobacteria,
Actinobacteria,
Chryseomonas,
Veillonella,
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Table 1. List of micro-organism that proposed have linkage in the progression of atherosclerosis.
Bacterias

Viruses:

Chlamydia pneumoniae
Helicobacter pylori
Borrelia burgdorferi
Pseudomonas aeroginosa
Mycoplasma pneumoniae
Oral plaque microbiota (multiple strains)
Gut microbiota (multiple strains)

Ebstein-Barr Virus (EBV)
Cytomegaly virus (CMV)
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Human immune deﬁciency virus (HIV)
Enterovirus
Inﬂuenza A virus
Herpes simplex virus 1 (HSV 1)
Fungi:
Funneliformis mosseae

Protozoa:
Perkinsus qugwadi

Streptococcus, Tannerella, Eikinella, Fusobacterium
and Campylobacter are some of the microbes that
have been isolated from atherosclerotic plaques
[37,38] (Table 2). Analyses with more complex and
speciﬁc techniques like pyrosequencing and next
generation DNA sequencing have led to the isolation and even discovery of new species within
atherosclerotic plaques [39e41]. Simultaneous
analysis of periodontal bioﬁlm and carotid plaques
also provides evidence for role of the oral microbiome in the atherosclerotic process. Nowadays, it is
accepted that chronic periodontal disease has a
strong impact on the progression of atherosclerosis
[33e38]. Besides the additional impact on the systemic inﬂammatory response, it may have a direct
effect on the vascular wall after translocation during
bacteremia.
The isolation of polymicrobial agents from
atherosclerotic plaques in all cases supports their
role in the symptomatology of the disease. Fak et al.
reported that patients with symptomatic atherosclerosis had a higher relative abundance of Anaeroglobus than the control group [26]. Especially
Parvimonas positivity within plaques indicates a
higher risk of plaque rupture and clinical manifestations. Range et al. reported that carotid plaques
involving Tannerella forsythia showed more prominent neutrophil activation and tended to complicate
more frequently [42]. On the other hand, Lindskog

et al. examined the different regions of the complicated carotid plaque in term of microbiome
involvement [10]. They found that the majority of
plaques involved Proteobacteria and Actinobacteria
and bacterial numbers were not statistically
different according to the symptomatology and region of the plaques. Although each study provided
variable results in term of symptomatology and
microbiologic involvement in the atherosclerotic
plaque, it is obviously clear that there is a strong
correlation between atherosclerosis and the oral
microbiota.
5.5. Gut microbiota
The gut microbiota includes a large variety of
microbiological species. Older traditional data have
suggested that they play only a minimal role in the
digestion process, while their metabolic effects are
unknown. After the completion of the Human
Genome Project, numerous investigations showed
the effect of the gut microbiota in systemic events
[14e17]. These studies conﬁrmed that the gut
microbiota has a direct effect on several systemic
diseases like obesity, diabetes mellitus, hypertension, coronary heart disease and some auto-immune
diseases. In the light of these studies, the gut
microbiota was deﬁned as a second brain, and
clinical trials are still ongoing. Parallel to evidence of

Table 2. Periodontal pathogens which proposed have a impact in the progression of atherosclerosis.
Most common oral pathogens

Most common bacterial species

Anaeroglobus
Firmicutes
Proteobacteria
Actinobacteria
Chryseomonas
Veillonella
Acinetobacter
Alloprevotella
Fusobacterium
Streptococcus

Porphyromonas gingivalis
Aggregatibacter actinomycetemcomitans
Tannerella forsythia
Eikenella corrodens
Fusobacterium nucleatum
Treponema denticola
Prevotella intermedia
Camplyobacter rectus

a linkage between the oral microbiota and atherosclerosis, recent studies have shown that there is a
close relationship between gut microbiota diversity
and atherosclerosis [11].
The gut microbiota may have an impact on
atherosclerosis either via direct invasion of atherosclerotic plaques or by modulating cholesterol
metabolism and the production of harmful metabolites. Gut microbes producing TMA are considered
harmful, whereas, bacteria producing propionic
acid and butyrate are thought to be beneﬁcial
[43,44]. Moreover, gut bacteria have a direct effect
on cholesterol metabolism. Gut bacteria may
change the absorption of cholesterol and fatty acids,
which may cause signiﬁcant changes in cholesterol
and triglyceride levels. The most common gut microbes associated with TMA accumulation are
indicated in Table 3.
Trimethylamine-N-oxide is an end metabolic
product of TMA. Recent studies have shown that an
increased serum TMAO level is a predictor of cardiovascular disease. It promotes forward cholesterol
transport, exacerbates impaired glucose tolerance
and promotes adipose tissue inﬂammation. All
these negative effects of TMAO have led to its
deﬁnition as a proatherogenic factor [43]. Serum
TMAO levels are dependent on gut TMA production from choline by the microbiota. Choline is
necessary for a wide range of biological activities,
including maintaining the structural integrity of cell
membranes, supporting cholinergic neurotransmission and donating methyl groups in biosynthetic
reactions. Choline availability depends on dietary
intake. Excessive metabolism of choline by gut
microbiota leads a deﬁciency of choline. Choline
metabolism can vary according to the composition
of the gut microbiota. Even with similar dietary
habits, gut TMA production may differ according to
the dominant species of the gut ﬂora [43].
In vitro studies have shown that two major
different phyla, Firmicutes and Proteobacteria, has the
capacity to consume choline accumulate TMA. In
contrast, Bacteroidetes colonization does not lead to
TMA accumulation, so it can be deﬁned as a beneﬁcial microbe [43]. Recent studies have proposed
that some anti-atherogenic molecules mediate their
effects by modulating the gut microbiota. The
beneﬁcial effect of berberine and resveratrol on
atherosclerosis are secondary to the modulation of
the gut microbiome [19,45]. Studies performed in
mice showed that both molecules mediate their effects by increasing the colonization of Lactobacillus
and Biﬁdobacterium, which have a low capacity for
TMA production. However, the majority of the gut
microbiota is still not cultivated, and we do not
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Table 3. Common gut microbes which associated with trimethylamine
accumulation.
Anaerococcus hydrogenalis
Clostridium asparagiforme
Clostridium hayhewayi
Clostridium sporogenes
Edwardsiella tarda
Escherichia fergusonii
Proteus penneri
Providencia rettgeri
Providencia rustiganii

know which phyla of the gut ﬂora may have an effect on atherosclerosis. In each study, several new
strains have been discovered that might have an
impact on the progression of atherosclerosis.
Ongoing studies and future investigations may
show further linkages between the gut microbiota
and atherosclerosis.
There is also linkage between heart failure and
gut microbiota such as increased Escherichia coli,
Klebsiella penumoniae, and Streptococcus viridans
[46]. Barin JG showed that gut microbial dysbiosis
may trigger autoimmune myocarditis and it may
lead to subsequent maladaptive cardiac remodeling
and heart failure. So, we can conclude that gut
microbiota have a signiﬁcant impact on the cardiac
function by the distant immugenic effects [47].

6. Treatment strategies for the Inﬂammatory
Aspects of Atherosclerosis
The basic approach to the treatment of atherosclerosis is primary prevention. The modiﬁcation of
risk factors including dyslipidemia, diabetes mellitus, hypertension and smoking is associated with a
lower incidence of cardiovascular disease [3]. The
major drugs used for secondary protection are lipidlowering drugs, antiplatelet drugs and antihypertensive drugs predominantly inﬂuencing the reninangiotensin system. Drugs that lower LDL levels are
still the cornerstone of the treatment of
atherosclerosis.
Vulnerable atherosclerotic plaques, deﬁned as
plaques with a lipid-rich core and a thin ﬁbrous
capsule, have a higher risk of complication. The
rupture of vulnerable plaques can lead to vascular
atherothrombosis, which is the major causes of
myocardial infarction and stroke. There is an active
inﬂammatory process within vulnerable plaques,
and stabilization of the such plaques could mitigate
clinical syndromes and lower mortality and
morbidity rates [3]. The major drugs used for the
stabilization of vulnerable plaques are statins and
angiotensin
receptor
inhibitors/angiotensin

REVIEW ARTICLE

JOURNAL OF THE SAUDI HEART ASSOCIATION 2020;32:440e450

446

JOURNAL OF THE SAUDI HEART ASSOCIATION 2020;32:440e450

REVIEW ARTICLE

receptor blockers. It has been proposed that they
mediate their stabilizing effects by modulating the
inﬂammatory cascade. The use of both drug groups
is associated with lower systemic inﬂammatory
markers. However, higher doses are necessary to
observe anti-inﬂammatory effects, and their effect is
relatively weak in terms of reversing the inﬂammatory cascade [3].
Inﬂammation plays a central role in the progression of atherosclerosis. Theoretically, suppressing
this inﬂammatory reaction might reverse the
atherosclerotic process [48]. Non-steroidal anti-inﬂammatory drugs (NSAIDs) are commonly used for
the treatment of local and systemic inﬂammation.
They inhibit prostaglandin synthesis and may exert
beneﬁcial effects on vascular inﬂammation. Contrary to expectation, studies with NSAIDs are associated with a higher rate of cardiovascular events
[48]. Inhibition of prostacyclin, which has an
important preventive effect on platelet aggregation,
counterbalances the probable beneﬁcial anti-inﬂammatory effects of these drugs. So, it is obviously
clear that NSAIDs are not effective at modulating
the inﬂammatory aspects of atherosclerosis.
A novel target for the treatment of inﬂammation
in atherosclerosis is blocking interleukin- 1b (IL-1b)
release from neutrophils. IL-1b plays important
roles in innate immunity and has an important effect in the initiation and complication of atherosclerosis [48,49]. The monoclonal antibody
canakinumab, a selective IL-1b inhibitor, was reported as being effective at decreasing the rate of
cardiovascular events after myocardial infarction
[48]. However, the cost of this therapy is high, and
further trials are necessary to show the effect on
stable patients. Studies with cheaper drugs that
affect IL-1b release showed variable results. IL-1b
has an important role in innate immunity [50e52].
Methotrexate is an anti-inﬂammatory drug used for
some autoimmune diseases. Methotrexate exerts its
anti-inﬂammatory effects partially by the inhibition
of IL-1b release. However, investigations with
methotrexate did not show similar results as those
with canakinumab. Inhibition of IL-1b production
with low-dose methotrexate did not show any
beneﬁcial effect on cardiovascular outcomes [50].
However, therapy with a low dose of colchicine,
another molecule that blocks IL-1b production,
seemed to be beneﬁcial and was associated with
lower serum inﬂammatory markers and fewer cardiovascular events [51,52].
Another novel therapeutic target is the inhibition
of toll-like receptors (TLRs), which play essential
roles in innate immunity [53]. TLRs are pattern
recognition receptors that mediate various signaling

pathways in infectious and sterile inﬂammation.
Some recent investigations have proposed that the
inhibition of TLRs alleviates the severity of atherosclerosis to some extent by suppressing vascular
inﬂammation and the formation of atherosclerotic
plaques [53]. The anti-inﬂammatory effect of statins,
particularly ﬂuvastatin, also occur by the inhibition
of TLR. However, we need more extensive investigations to elucidate the favorable effect of TLR
inhibitors.
It is logical to postulate that the eradication of
microbial agents that are assumed to have an effect
on atherosclerosis could modulate the atherosclerotic process. To check the validity of this hypothesis, antibiotic therapy was investigated to assess the
effect on atherosclerosis. These studies did not show
any beneﬁcial effects of antibiotics on cardiovascular
events. In these studies, the composition of the
microbiota was not analyzed. Antibiotics induced
the dysbiosis of gut microbiota and may have
reversed the beneﬁcial effects of antibiotics. Nonetheless, early and effective treatment of C. pneumoniae, M.pneumoniae, H.pylori and other predeﬁned
bacteria may prevent the dissemination of such
species and decrease the likelihood of vascular
invasion.
Modulation of the oral ﬂora is very important to
treat the inﬂammatory causes of atherosclerosis.
Regular oral examination may show the degree of
periodontitis, which has been linked to more
frequent cardiovascular events. Treatment of
chronic periodontitis with antiseptic solutions and
regular tooth-brushing may decrease the level of
inﬂammation. Cultivation of the oral ﬂora in
advanced periodontitis patients and even antibiotic
therapy for certain harmful species might have an
impact on the systemic inﬂammatory response.
The role of the gut microbiota in the progression
of atherosclerosis is more complex. An unhealthy
diet and prolonged antibiotic treatment may lead to
dysbiosis and the accumulation of harmful TMA
and short-chain fatty acids. Novel investigations
have focused on the inhibition of the conversion of
TMA to the pro-atherogenic compound TMAO,
which may show promising effects in terms of
slowing the atherosclerotic process [54]. External
intake of certain beneﬁcial probiotics may have
beneﬁcial effects on the inﬂammatory aspects of
atherosclerosis.

7. Future Perspectives
Atherosclerosis is a complex progressive vascular
disease and is a major cause of disability, morbidity
and mortality. As the mean age of the population

gets older, atherosclerosis will continue to be a
major concern regarding the quality and duration of
life in the next century. The demographic and clinical predictors of atherosclerosis are well-deﬁned.
Genetic predisposition, dyslipidemia, hypertension,
diabetes mellitus, smoking, sedentary lifestyle and
unhealthy nutrition are all well-known predictors of
atherosclerosis. Moreover, numerous biochemical
blood markers including hematological indices,
homocysteine, uric acid and inﬂammatory markers
have been proposed as contributors to atherosclerosis. Control of the clinical contributors, especially
dyslipidemia and diabetes, is associated with more
favorable clinical endpoints associated with atherosclerosis. However, treating the inﬂammatory aspects of atherosclerosis is still debatable. Infectious
agents are the leading cause of the inﬂammatory
response in the body and numerous infectious
agents have been proposed to have an impact on the
progression of atherosclerosis. C. pneumoniae was
the ﬁrst infectious agent isolated from atherosclerotic plaques. Antibiotic therapy to eradicate C.
pneumoniae infection did not change the progression
of atherosclerosis. These studies indicate the effect
of multiple infectious agents in atherosclerosis.
Recent studies have focused on the effect of oral
ﬂora and gut microbiota. The number of microbes in
the gastro-intestinal ﬂora is greater than the total
number of eukaryotic cells in the body. Translocation of such bacteria to the blood stream and
colonization of the vascular wall is easy; thus, simple
tooth-brushing may cause transient bacteremia.
Simple antibiotic use for a local infection may
change the microbial diversity in the bowel and
facilitate the colonization and translocation of virulent microbes. For a deﬁnitive explanation of the
inﬂammatory aspects of atherosclerosis, future investigations concerning the oral and gut microbiota
should clarify the linkage between infectious agent
and atherosclerosis. We already know that certain
strains in the oral and gut ﬂora are associated with
atherosclerosis. Colonization of relatively healthy
strains may decrease the risk of atherosclerotic
vascular disease. However, it is not known whether
the inoculation of some strains has an additional
beneﬁcial effect on the progression of atherosclerosis. Thus, we can form a hypothesis similar to
HDL cholesterol management. Lower HDL cholesterol levels are the strongest risk factor for atherosclerosis. Bringing up HDL levels to the normal
range may attenuate the atherosclerotic process.
However, the elevation of HDL over the normal
range does not have a beneﬁcial effect; on contrary,
it might have deleterious effects in atherosclerosis.
We can propose a similar scenario in the correlation
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between the gut microbiota and atherosclerosis. All
the beneﬁcial effects of the gut microbiota were
deﬁned in the absence of the deleterious effects of
virulent microorganisms. So, we can propose that a
beneﬁcial gut microbiota is a relative term to
describe the elimination of the negative impact of
certain virulent strains. It means that we may deﬁne
innocent microorganisms as beneﬁcial, although
they might have neutral effects on atherosclerosis.
Colonization of the gut mucosa with a single bacterial species which was previously approved as
beneﬁcial may not show favorable effects on
atherosclerosis and might even be harmful. To reach
a more deﬁnitive conclusion, further investigations
should be perform to show a correlation between
probiotics that are assumed to be beneﬁcial and
slowing down the progression of atherosclerosis.
The current unarguable truth is that keeping away
some predeﬁned strains from the gastro-intestinal
microbiota may have favorable effects on
atherosclerosis.
Deﬁnitive treatment of the inﬂammatory aspects
of atherosclerosis may become more convincing
after large-scale future investigations. Inhibition of
IL-1b is a promising therapy and may become
commercially available for clinical usage. However,
the debate over speciﬁc therapies for microbial
agents and atherosclerotic progression will
continue.

8. Executive Summary
8.1. Atherosclerosis
Atherosclerosis is chronic, progressive inﬂammatory disease of the arterial wall. It is a leading cause
of morbidity and mortality all over the world. The
clinical and demographic contributors of atherosclerosis are well-deﬁned. Systemic diseases
including dyslipidemia, diabetes, hypertension and
renal failure are the major proposed predisposing
factors for atherosclerosis. Genetic predisposition,
smoking, unhealthy lifestyle are the other basic
factors implicated in the development of
atherosclerosis.
8.2. Inﬂammation and atherosclerosis
The general consensus states that inﬂammation
plays a central role in the development of atherosclerosis. The inﬂammatory cascade in the vascular
wall that initiates the atherosclerotic process is welldeﬁned. Direct analysis of atherosclerotic plaques
has shown prominent inﬁltration of inﬂammatory
cells
and
cytokines.
In
addition,
serum
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inﬂammatory markers, including hematological
indices, CRP, IL-1, IL-6, procalcitonin and some
cytokines, have been reported as predictors of
atherosclerosis. However, the predictors and contributors of the inﬂammatory response in the
vascular wall are still an arguable issue. Systemic
and local inﬂammation, which enhance the burden
of inﬂammation in the vascular wall, have been
proposed as risk factors for the progression of
atherosclerosis. Moreover, some systemic autoimmune diseases like rheumatoid arthritis and psoriasis may enhance inﬂammation in the vascular wall.
8.3. Microbial agents and atherosclerosis
Infectious micro-organisms are one of the major
triggering factors of local and systemic inﬂammation. Microbial agents may accentuate inﬂammation
in the vascular wall by increasing the intensity of the
systemic inﬂammatory response. To clarify the inﬂammatory aspects of atherosclerosis, numerous
investigations have been performed to show the
linkage
between
microbial
agents
and
atherosclerosis.
8.4. Chlamydia pneumoniae and atherosclerosis
Chlamydia pneumoniae was the ﬁrst microbial
agent isolated from atherosclerotic plaques. Analysis of both carotid and coronary atherosclerotic
plaques showed the dissemination and colonization
of the C.pneumoniae within the vascular wall and in
atherosclerotic plaques. It was also reported that
carotid plaques infected with C. pneumoniae tend to
complicate and lead to clinical syndromes more
frequently. Subsequently, additional bacterial and
viral agents have been isolated from human
atherosclerotic plaques.
8.5. Microbiota and atherosclerosis
After proposing a linkage between atherosclerosis
and microbial agents, further investigations were
focused on the impact of the oral and gut ﬂora.
Translocation and bacteremia with the oral and gut
microbiota have been observed. Simple toothbrushing may lead to transient bacteremia. Antibiotics and an unhealthy diet may easily change the
composition of the gut microbiota. The colonization
of certain bacterial species may enhance atherosclerosis, either directly or indirectly. The accumulation of trimethylamine by certain detrimental
bacterial species may accelerate the atherosclerotic
process.

8.6. Conclusion and future perspectives
These studies concluded that micro-organisms
have an important effect on the initiation, progression and complication of atherosclerotic plaques.
Although initial antibiotic treatment trials failed to
show an effect on atherosclerosis, recent investigations with gut microbiota have shown more
promising results. The prevention of colonization
with certain strains in the gut ﬂora may have
beneﬁcial effects on the progression of atherosclerosis. Further investigations would clarify the cause
and effect linkage between microbiological agents
and atherosclerosis.
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